

Roberto Giacomelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7502015/publications.pdf>

Version: 2024-02-01

322
papers

11,490
citations

20759

60
h-index

48187

88
g-index

324
all docs

324
docs citations

324
times ranked

11545
citing authors

#	ARTICLE	IF	CITATIONS
1	Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, S51-S131.	1.5	582
2	European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 592-598.	0.5	271
3	A comprehensive review on adult onset Still's disease. <i>Journal of Autoimmunity</i> , 2018, 93, 24-36.	3.0	262
4	Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?. <i>Autoimmunity Reviews</i> , 2020, 19, 102524.	2.5	231
5	Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. <i>Arthritis Research</i> , 2002, 4, R11.	2.0	230
6	Angiogenesis in rheumatoid arthritis: A disease specific process or a common response to chronic inflammation?. <i>Autoimmunity Reviews</i> , 2011, 10, 595-598.	2.5	168
7	Vascular complications of scleroderma. <i>Autoimmunity Reviews</i> , 2007, 6, 520-523.	2.5	157
8	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012, 12, 225-229.	2.5	146
9	The Role of IL-1 in the Bone Loss during Rheumatic Diseases. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	1.4	146
10	Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. <i>Arthritis Research and Therapy</i> , 2013, 15, R172.	1.6	143
11	Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: New insight into the pathogenesis of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007, 56, 1994-2004.	6.7	138
12	Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2021, 20, 102735.	2.5	135
13	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1042-1050.	0.5	132
14	Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. <i>BMC Medicine</i> , 2016, 14, 194.	2.3	130
15	Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: Results of a multicenter study. <i>Journal of Autoimmunity</i> , 2014, 51, 75-80.	3.0	126
16	Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. <i>Gut</i> , 2000, 47, 410-414.	6.1	121
17	Infliximab in spondyloarthritis associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1664-1669.	0.5	113
18	Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population-based multicentre cohort study. <i>Journal of Internal Medicine</i> , 2015, 278, 185-192.	2.7	110

#	ARTICLE	IF	CITATIONS
19	Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1788-1792.	0.5	107
20	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, etc.) <i>Trends in Rheumatology</i> , 2019, 19, 107-110.	2.5	107
21	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 93-106.	2.5	101
22	Methotrexate: an old new drug in autoimmune disease. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1519-1530.	1.3	100
23	Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1 β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3 (NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. <i>Clinical and Experimental Immunology</i> , 2015, 182, 35-44.	1.1	100
24	The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 598-605.	0.5	97
25	Interleukin-36 axis is modulated in patients with primary Sjögren's syndrome. <i>Clinical and Experimental Immunology</i> , 2015, 181, 230-238.	1.1	95
26	Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. <i>PLoS Medicine</i> , 2019, 16, e1002901.	3.9	94
27	Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. <i>Journal of Rheumatology</i> , 2002, 29, 731-6.	1.0	93
28	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 369.	1.6	89
29	Angiogenic cytokines and growth factors in systemic sclerosis. <i>Autoimmunity Reviews</i> , 2011, 10, 590-594.	2.5	88
30	Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. <i>Arthritis Research and Therapy</i> , 2014, 16, R144.	1.6	88
31	EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 163-168.	0.5	87
32	Cytokines in the pathogenesis of rheumatoid arthritis: new players and therapeutic targets. <i>BMC Rheumatology</i> , 2017, 1, 3.	0.6	87
33	Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases. <i>Autoimmunity Reviews</i> , 2019, 18, 102369.	2.5	86
34	Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. <i>Clinical Rheumatology</i> , 2014, 33, 49-55.	1.0	84
35	European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 585-591.	0.5	83
36	Immunomodulation in psoriatic arthritis: Focus on cellular and molecular pathways. <i>Autoimmunity Reviews</i> , 2013, 12, 599-606.	2.5	83

#	ARTICLE	IF	CITATIONS
37	Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. <i>Clinical Rheumatology</i> , 2016, 35, 1683-1689.	1.0	83
38	Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphoma. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1588-1599.	0.5	83
39	The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor- β 2 and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. <i>Journal of Rheumatology</i> , 2015, 42, 1808-1816.	1.0	82
40	Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. <i>Autoimmunity Reviews</i> , 2015, 14, 1019-1022.	2.5	80
41	Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1922-1931.	2.9	80
42	Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. <i>Frontiers in Immunology</i> , 2020, 11, 1130.	2.2	79
43	Rheumatic manifestations of COVID-19: a systematic review and meta-analysis. <i>BMC Rheumatology</i> , 2020, 4, 65.	0.6	78
44	Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. <i>Rheumatology</i> , 2008, 47, 646-651.	0.9	76
45	Interstitial lung disease in systemic sclerosis: current and future treatment. <i>Rheumatology International</i> , 2017, 37, 853-863.	1.5	76
46	High Levels of Peripheral Blood NK Cells in Women Suffering from Recurrent Spontaneous Abortion are Reverted from High-Dose Intravenous Immunoglobulins. <i>American Journal of Reproductive Immunology</i> , 2006, 55, 232-239.	1.2	75
47	Computed Tomography and MR Imaging in Rheumatoid Arthritis. <i>Radiologic Clinics of North America</i> , 2017, 55, 997-1007.	0.9	74
48	Cytokine storm syndrome in severe COVID-19. <i>Autoimmunity Reviews</i> , 2020, 19, 102562.	2.5	72
49	Fibromyalgia: a new facet of the post-COVID-19 syndrome spectrum? Results from a web-based survey. <i>RMD Open</i> , 2021, 7, e001735.	1.8	72
50	Circulating V β 1 + T cells are activated and accumulate in the skin of systemic sclerosis patients. <i>Arthritis and Rheumatism</i> , 1998, 41, 327-334.	6.7	70
51	Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort. <i>Journal of Rheumatology</i> , 2018, 45, 864-872.	1.0	70
52	Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. <i>Clinical and Experimental Immunology</i> , 2008, 81, 368-372.	1.1	67
53	Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. <i>Rheumatology</i> , 2015, 54, 792-797.	0.9	67
54	Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). <i>European Journal of Radiology</i> , 2013, 82, e268-e273.	1.2	66

#	ARTICLE	IF	CITATIONS
55	Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders. <i>Autoimmunity Reviews</i> , 2018, 17, 366-375.	2.5	66
56	GM-CSF and Pregnancy: Evidence of Significantly Reduced Blood Concentrations in Unexplained Recurrent Abortion Efficiently Reverted by Intravenous Immunoglobulin Treatment. <i>American Journal of Reproductive Immunology</i> , 2003, 50, 232-237.	1.2	65
57	Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. <i>Autoimmunity Reviews</i> , 2017, 16, 16-21.	2.5	65
58	Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications. <i>Arthritis and Rheumatism</i> , 2006, 54, 3022-3033.	6.7	64
59	Lymphoma and Lymphomagenesis in Primary Sjögren's Syndrome. <i>Frontiers in Medicine</i> , 2018, 5, 102.	1.2	64
60	A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren's syndrome. <i>Lupus</i> , 2015, 24, 315-320.	0.8	63
61	High levels of NK cells in the peripheral blood of patients affected with anti-phospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis. <i>Rheumatology</i> , 2007, 46, 1574-1578.	0.9	62
62	Methotrexate in Rheumatoid Arthritis: Optimizing Therapy Among Different Formulations. <i>Current and Emerging Paradigms. Clinical Therapeutics</i> , 2014, 36, 427-435.	1.1	62
63	Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. <i>Angiogenesis</i> , 2013, 16, 595-607.	3.7	61
64	Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: A retrospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 314-324.	1.6	61
65	CD4 ⁺ CD8 ⁻ T-cells in primary Sjögren's syndrome: Association with the extent of glandular involvement. <i>Journal of Autoimmunity</i> , 2014, 51, 38-43.	3.0	60
66	Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. <i>Clinical and Experimental Immunology</i> , 2013, 173, 195-206.	1.1	59
67	T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	1.4	59
68	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , 2020, 59, 2350-2359.	0.9	54
69	Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. <i>Clinical Rheumatology</i> , 2017, 36, 2839-2845.	1.0	53
70	Cellular players in angiogenesis during the course of systemic sclerosis. <i>Autoimmunity Reviews</i> , 2011, 10, 641-646.	2.5	52
71	Vitamin D and systemic lupus erythematosus - The hype and the hope. <i>Autoimmunity Reviews</i> , 2018, 17, 19-23.	2.5	52
72	Increase of circulating β_2 T lymphocytes in the peripheral blood of patients affected by active inflammatory bowel disease. <i>Clinical and Experimental Immunology</i> , 2008, 98, 83-88.	1.1	51

#	ARTICLE	IF	CITATIONS
73	Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. <i>Autoimmunity Reviews</i> , 2013, 12, 709-716.	2.5	51
74	Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 36-41.	0.6	51
75	Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. <i>Clinical and Experimental Immunology</i> , 1997, 108, 42-46.	1.1	49
76	Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. <i>Arthritis Research and Therapy</i> , 2014, 16, 442.	1.6	49
77	Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 249-252.	0.5	46
78	Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. <i>Autoimmunity Reviews</i> , 2015, 14, 429-437.	2.5	46
79	IL-1 β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 849-855.	1.3	46
80	PTP4A1 promotes TGF β 2 signaling and fibrosis in systemic sclerosis. <i>Nature Communications</i> , 2017, 8, 1060.	5.8	46
81	Familial autoimmunity as a risk factor for systemic lupus erythematosus and vice versa: a case-control study. <i>Lupus</i> , 2003, 12, 735-740.	0.8	45
82	Serologic Profile and Mortality Rates of Scleroderma Renal Crisis in Italy. <i>Journal of Rheumatology</i> , 2009, 36, 1464-1469.	1.0	45
83	Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis. <i>Journal of Rheumatology</i> , 2016, 43, 1340-1349.	1.0	45
84	Surface Expression of Fractalkine Receptor (CX3CR1) on CD4+/CD28 T Cells in RA Patients and Correlation with Atherosclerotic Damage. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 32-41.	1.8	43
85	Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis. <i>Medicine (United States)</i> , 2017, 96, e7896.	0.4	42
86	Biologic drugs in adult onset Still's disease: a systematic review and meta-analysis of observational studies. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1089-1097.	1.3	42
87	Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. <i>PLoS ONE</i> , 2017, 12, e0181203.	1.1	42
88	A genetic variation located in the promoter region of the <i>UPAR</i> (<i>CD87</i>) gene is associated with the vascular complications of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 247-256.	6.7	41
89	Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome. <i>Rheumatology</i> , 2014, 53, 1313-1320.	0.9	41
90	Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence radiological differences. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1152-1155.	0.5	41

#	ARTICLE	IF	CITATIONS
91	Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. PLoS ONE, 2017, 12, e0170108.	1.1	41
92	H-ferritin and CD68+/H-ferritin+ monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease. Clinical and Experimental Immunology, 2016, 186, 30-38.	1.1	40
93	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Arthritis Research and Therapy, 2019, 21, 204.	1.6	40
94	Circulating $\hat{I}^3\hat{I}^T$ T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clinical and Experimental Immunology, 2001, 125, 310-315.	1.1	39
95	Association of a Functional Polymorphism in the Matrix Metalloproteinase-12 Promoter Region with Systemic Sclerosis in an Italian Population. Journal of Rheumatology, 2010, 37, 1852-1857.	1.0	39
96	Interleukin-9 over-expression and T helper 9 polarization in systemic sclerosis patients. Clinical and Experimental Immunology, 2017, 190, 208-216.	1.1	39
97	Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjögren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18. Clinical and Experimental Immunology, 2015, 181, 219-229.	1.1	38
98	H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome. Clinical and Experimental Immunology, 2018, 191, 220-228.	1.1	38
99	Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations. Scientific Reports, 2020, 10, 12232.	1.6	38
100	Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity's characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. Arthritis Research and Therapy, 2020, 22, 151.	1.6	38
101	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. Autoimmunity Reviews, 2021, 20, 102738.	2.5	38
102	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 102-112.	0.4	37
103	The Italian version of the Family Assessment Device. Social Psychiatry and Psychiatric Epidemiology, 1998, 33, 451-461.	1.6	36
104	Complement System and Rheumatoid Arthritis: Relationships with Autoantibodies, Serological, Clinical Features, and Anti-TNF Treatment. International Journal of Immunopathology and Pharmacology, 2011, 24, 357-366.	1.0	36
105	Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: A new era for therapeutic targeting?. Autoimmunity Reviews, 2014, 13, 1167-1173.	2.5	36
106	Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?. Expert Review of Clinical Immunology, 2017, 13, 1041-1047.	1.3	36
107	Pathogenesis of adult onset still's disease: current understanding and new insights. Expert Review of Clinical Immunology, 2018, 14, 965-976.	1.3	36
108	IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes. Medicine (United States), 2019, 98, e14587.	0.4	36

#	ARTICLE	IF	CITATIONS
109	Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1515-1516.	0.5	36
110	Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?. <i>Autoimmunity Reviews</i> , 2021, 20, 102750.	2.5	36
111	Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn's disease (CD). <i>Clinical and Experimental Immunology</i> , 1998, 111, 532-535.	1.1	35
112	Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma). <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 487-494.	0.5	35
113	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	1.6	35
114	The γ 670G>A polymorphism in the <i>FAS</i> gene promoter region influences the susceptibility to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 584-590.	0.5	34
115	Post-Translational Modifications of Proteins: Novel Insights in the Autoimmune Response in Rheumatoid Arthritis. <i>Cells</i> , 2019, 8, 657.	1.8	34
116	Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study. <i>Rheumatology International</i> , 2020, 40, 951-958.	1.5	34
117	Polyclonal B lymphocyte activation in progressive systemic sclerosis. <i>Journal of Clinical & Laboratory Immunology</i> , 1989, 29, 59-63.	0.1	34
118	Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue. <i>Journal of Rheumatology</i> , 2017, 44, 1179-1183.	1.0	33
119	Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. <i>Journal of Rheumatology</i> , 1996, 23, 291-6.	1.0	33
120	Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study. <i>Clinical and Experimental Immunology</i> , 2016, 184, 284-292.	1.1	32
121	Safety and efficacy of intra-articular anti-tumor necrosis factor $\hat{\pm}$ agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. <i>International Journal of Immunopathology and Pharmacology</i> , 2016, 29, 252-266.	1.0	32
122	Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 440-441.	0.5	32
123	Anti-hnRNP and other autoantibodies in systemic sclerosis with joint involvement. <i>Rheumatology</i> , 2009, 48, 920-925.	0.9	31
124	Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?. <i>Autoimmunity Reviews</i> , 2015, 14, 575-578.	2.5	31
125	Phenotypical and Functional Characteristics of in Vitro-Expanded Adipose-Derived Mesenchymal Stromal Cells from Patients with Systemic Sclerosis. <i>Cell Transplantation</i> , 2017, 26, 841-854.	1.2	31
126	Clinical, Epidemiological, and Histopathological Features of Respiratory Involvement in Rheumatoid Arthritis. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	31

#	ARTICLE	IF	CITATIONS
127	Cardiovascular and Metabolic Comorbidities in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2018, 20, 81.	2.1	31
128	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. <i>PLoS ONE</i> , 2020, 15, e0235326.	1.1	31
129	Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 408-411.	0.5	29
130	Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 782-783.	0.5	29
131	Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1727-1737.	1.4	29
132	The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: correlation with disease severity and implication for pathogenesis. <i>Clinical and Experimental Immunology</i> , 2016, 183, 397-404.	1.1	29
133	Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy. <i>Arthritis Research and Therapy</i> , 2018, 20, 223.	1.6	29
134	Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. <i>Journal of Medical Case Reports</i> , 2015, 9, 123.	0.4	28
135	Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. <i>Medicine (United Kingdom)</i> , 2017, 96, e014314.	0.7	27
136	Myositis in primary Sjogren's syndrome: data from a multicentre cohort. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 457-64.	0.4	27
137	Scleroderma fibroblasts suppress angiogenesis via TGF- β 2/caveolin-1 dependent secretion of pigment epithelium-derived factor. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 431-440.	0.5	26
138	A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjogren's syndrome. <i>Rheumatology</i> , 2021, 60, 1364-1375.	0.9	26
139	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 918.	1.6	25
140	Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 213.	1.6	25
141	T lymphocytes in the synovial fluid of patients with active rheumatoid arthritis display CD134-OX40 surface antigen. <i>Clinical and Experimental Rheumatology</i> , 2001, 19, 317-20.	0.4	25
142	Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2014, 7, 13.	3.4	24
143	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF- α Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. <i>Mediators of Inflammation</i> , 2020, 2020, 1-12.	1.4	24
144	Childhood-onset of primary Sjogren's syndrome: phenotypic characterization at diagnosis of 158 children. <i>Rheumatology</i> , 2021, 60, 4558-4567.	0.9	24

#	ARTICLE	IF	CITATIONS
145	Interferon gamma-inducible protein 16 in primary Sjögren's syndrome: a novel player in disease pathogenesis?. <i>Arthritis Research and Therapy</i> , 2015, 17, 208.	1.6	23
146	The effect of non-TNF-targeted biologics and small molecules on insulin resistance in inflammatory arthritis. <i>Autoimmunity Reviews</i> , 2018, 17, 399-404.	2.5	23
147	Dissecting the clinical heterogeneity of adult-onset Still's disease: results from a multi-dimensional characterization and stratification. <i>Rheumatology</i> , 2021, 60, 4844-4849.	0.9	23
148	The role of innate and lymphoid IL-22-producing cells in the immunopathology of primary Sjögren's syndrome. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 533-541.	1.3	22
149	Macitentan inhibits the transforming growth factor- β^2 profibrotic action, blocking the signaling mediated by the ETR/ T^2RI complex in systemic sclerosis dermal fibroblasts. <i>Arthritis Research and Therapy</i> , 2015, 17, 247.	1.6	22
150	Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. <i>Clinical Rheumatology</i> , 2017, 36, 251-260.	1.0	22
151	Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1247-1254.	0.4	22
152	The Effect of Ketogenic Diet on Inflammatory Arthritis and Cardiovascular Health in Rheumatic Conditions: A Mini Review. <i>Frontiers in Medicine</i> , 2021, 8, 792846.	1.2	22
153	Rituximab in primary Sjögren's syndrome: a ten-year journey. <i>Lupus</i> , 2014, 23, 1337-1349.	0.8	21
154	Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis. <i>Medicine (United States)</i> , 2017, 96, e8180.	0.4	21
155	The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. <i>Modern Rheumatology</i> , 2018, 28, 922-932.	0.9	21
156	Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment. <i>Rheumatology and Therapy</i> , 2020, 7, 867-882.	1.1	21
157	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020, 7, 42.	1.2	21
158	Metabolic Syndrome and psoriatic arthritis: considerations for the clinician. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 409-420.	1.3	21
159	Endothelial-to-mesenchymal transition in systemic sclerosis. <i>Clinical and Experimental Immunology</i> , 2021, 205, 12-27.	1.1	21
160	Natural killer activity and antibody-dependent cellular cytotoxicity in progressive systemic sclerosis. <i>Clinical and Experimental Immunology</i> , 2008, 80, 360-365.	1.1	20
161	The Impact of Fibromyalgia in Spondyloarthritis: From Classification Criteria to Outcome Measures. <i>Frontiers in Medicine</i> , 2018, 5, 290.	1.2	20
162	Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities. <i>Journal of Immunology Research</i> , 2018, 2018, 1-10.	0.9	20

#	ARTICLE	IF	CITATIONS
163	Downregulation of miRNA17â€“92 cluster marks VÎ³9VÎ² T cells from patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 236.	1.6	20
164	Celiac Disease Prevalence Is Increased in Primary SjÃ¶rgrenâ€™s Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 540.	1.0	20
165	The effect of non-TNF-targeted biologics on vascular dysfunction in rheumatoid arthritis: A systematic literature review. <i>Autoimmunity Reviews</i> , 2019, 18, 501-509.	2.5	20
166	Prescribing motivations and patientsâ€™ characteristics related to the use of biologic drugs in adult-onset Stillâ€™s disease: analysis of a multicentre â€œreal-lifeâ€•cohort. <i>Rheumatology International</i> , 2020, 40, 107-113.	1.5	20
167	Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemoinvasion and proliferation in rheumatoid arthritis synoviocytes. <i>Rheumatology</i> , 2005, 44, 1255-1262.	0.9	19
168	Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. <i>Cytotherapy</i> , 2015, 17, 832-849.	0.3	19
169	Insulin Signaling in Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 672519.	2.2	19
170	Variations of neuronal nitric oxide synthase in systemic sclerosis skin. <i>Arthritis and Rheumatism</i> , 2006, 54, 202-213.	6.7	18
171	Jejunioileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 441-452.	1.3	18
172	Interleukinâ€“25 Axis Is Involved in the Pathogenesis of Human Primary and Experimental Murine SjÃ¶rgren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 1265-1275.	2.9	18
173	Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling. <i>Scientific Reports</i> , 2019, 9, 7144.	1.6	18
174	Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study. <i>Arthritis Research and Therapy</i> , 2019, 21, 286.	1.6	18
175	Levels and Factors Associated with Resilience in Italian Healthcare Professionals during the COVID-19 Pandemic: A Web-Based Survey. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2020, 10, 183.	1.0	18
176	Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. <i>Arthritis Research and Therapy</i> , 2020, 22, 127.	1.6	18
177	Circulating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patients. <i>Clinical and Experimental Immunology</i> , 1999, 115, 72-77.	1.1	17
178	Damage of cutaneous peripheral nervous system evolves differently according to the disease phase and subset of systemic sclerosis. <i>Rheumatology</i> , 2005, 44, 607-613.	0.9	17
179	Clinical features and prognosis of COVID-19 in people with spinal cord injury: a caseâ€“control study. <i>Spinal Cord Series and Cases</i> , 2020, 6, 69.	0.3	16
180	The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Stillâ€™s disease. A systematic review and meta-analysis of observational studies. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093313.	1.2	16

#	ARTICLE	IF	CITATIONS
181	Hyperuricemia in Psoriatic Arthritis: Epidemiology, Pathophysiology, and Clinical Implications. <i>Frontiers in Medicine</i> , 2021, 8, 737573.	1.2	16
182	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. <i>Rheumatology</i> , 2022, 61, 4124-4129.	0.9	16
183	Impaired Human Ovarian Follicular Fluid Complement Function in Hereditary Angioedema. <i>Scandinavian Journal of Immunology</i> , 2000, 51, 104-108.	1.3	15
184	Inhibition of the Complement System by Glutathione: Molecular Mechanisms and Potential Therapeutic Implications. <i>International Journal of Immunopathology and Pharmacology</i> , 2011, 24, 63-68.	1.0	15
185	Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1247-1260.	0.9	15
186	Patients' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2153-2168.	0.8	15
187	Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. <i>Rheumatology</i> , 2021, 60, 728-736.	0.9	15
188	The Pathogenic Role of Interferons in the Hyperinflammatory Response on Adult-Onset Still's Disease and Macrophage Activation Syndrome: Paving the Way towards New Therapeutic Targets. <i>Journal of Clinical Medicine</i> , 2021, 10, 1164.	1.0	15
189	Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis. <i>Journal of Rheumatology</i> , 2006, 33, 2003-14.	1.0	15
190	Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still's disease. <i>Rheumatology</i> , 2022, 62, 321-329.	0.9	15
191	Non organ based laboratory markers in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2003, 21, S32-8.	0.4	14
192	Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: the experience of two Italian integrated Dermatology/Rheumatology outpatient clinics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2160-2168.	1.3	13
193	Endothelial progenitor cells: Are they displaying a function in autoimmune disorders?. <i>Mechanisms of Ageing and Development</i> , 2016, 159, 44-48.	2.2	13
194	Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 593-604.	1.3	13
195	Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trial. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 403-406.	0.4	13
196	Piascledine modulates the production of VEGF and TIMP-1 and reduces the invasiveness of rheumatoid arthritis synoviocytes. <i>Scandinavian Journal of Rheumatology</i> , 2006, 35, 346-350.	0.6	12
197	Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts. <i>Scientific Reports</i> , 2019, 9, 4589.	1.6	12
198	Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 119-128.	1.3	12

#	ARTICLE	IF	CITATIONS
199	The wide spectrum of Kawasaki-like disease associated with SARS-CoV-2 infection. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1205-1215.	1.3	12
200	Incidence, prevalence and mortality of systemic sclerosis in Italy: a nationwide population-based study using administrative health data. <i>Rheumatology International</i> , 2021, 41, 129-137.	1.5	12
201	Peripheral Nervous System Involvement in Sjögren's Syndrome: Analysis of a Cohort From the Italian Research Group on Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 615656.	2.2	12
202	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. <i>Rheumatology</i> , 2022, 62, 243-255.	0.9	12
203	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 166-174.	0.4	12
204	Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications. <i>Autoimmunity Reviews</i> , 2022, 21, 103114.	2.5	12
205	Stem cell therapies for systemic sclerosis. <i>British Journal of Haematology</i> , 2015, 168, 328-337.	1.2	11
206	Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands. <i>PLoS ONE</i> , 2019, 14, e0211142.	1.1	11
207	Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNFalpha production without decreasing TNFalpha mRNA levels. An in vivo and in vitro study. <i>Clinical and Experimental Rheumatology</i> , 2002, 20, 365-72.	0.4	11
208	The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn). <i>Clinical and Experimental Rheumatology</i> , 2005, 23, 671-7.	0.4	11
209	The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. <i>Scientific Reports</i> , 2021, 11, 12455.	1.6	10
210	Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review). <i>Molecular Medicine Reports</i> , 2019, 20, 1488-1498.	1.1	10
211	The Vessels Contribute to Fibrosis in Systemic Sclerosis. <i>Israel Medical Association Journal</i> , 2019, 21, 471-474.	0.1	10
212	The clinical heterogeneity of adult onset Still's disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients. <i>Seminars in Immunology</i> , 2021, 58, 101632.	2.7	10
213	Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature. <i>Rheumatology</i> , 2018, 57, vii23-vii31.	0.9	9
214	Histopathology of salivary glands. <i>Reumatismo</i> , 2018, 70, 146-154.	0.4	9
215	Multicenter Validation of the DETAIL Questionnaire for the Screening of Spondyloarthritis in Patients With Inflammatory Bowel Diseases. <i>Journal of Rheumatology</i> , 2021, 48, 179-187.	1.0	9
216	Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE). <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 24-32.	0.4	9

#	ARTICLE	IF	CITATIONS
217	The kaleidoscope of neurological manifestations in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 192-198.	0.4	9
218	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. <i>Frontiers in Medicine</i> , 2022, 9, 878797.	1.2	9
219	Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2005, 7, R1244.	1.6	8
220	Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 785-796.	0.9	8
221	The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 187-195.	0.4	8
222	Ferritin and Severe COVID-19, from Clinical Observations to Pathogenic Implications and Therapeutic Perspectives. <i>Israel Medical Association Journal</i> , 2020, 22, 516-518.	0.1	8
223	Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis. <i>Archives of Medical Science</i> , 2016, 4, 828-843.	0.4	7
224	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. <i>Mediators of Inflammation</i> , 2020, 2020, 1-6.	1.4	7
225	Pathogenic implications, incidence, and outcomes of COVID-19 in autoimmune inflammatory joint diseases and autoinflammatory disorders. <i>Advances in Rheumatology</i> , 2021, 61, 45.	0.8	7
226	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 471-484.	1.9	7
227	Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases. <i>Clinical Rheumatology</i> , 2022, 41, 2261-2267.	1.0	7
228	Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. <i>Scientific Reports</i> , 2022, 12, 7498.	1.6	7
229	Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF- β 2 and IL-6. <i>Pharmaceutics</i> , 2022, 15, 622.	1.7	7
230	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	0.9	7
231	Familial scleroderma: Do environmental factors, genes and microchimerism share the same relevance?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2001, 15, 11-14.	1.3	6
232	The classification criteria for Sjögren syndrome: issues for their improvement from the study of a large Italian cohort of patients. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e35-e35.	0.5	6
233	The role of T helper 17 cell subsets in Sjögren's syndrome: similarities and differences between mouse model and humans. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e42-e42.	0.5	6
234	Hepatitis E infection in a patient with rheumatoid arthritis treated with leflunomide. <i>Medicine (United Kingdom)</i> , 2014, 93, 1000-1004.	0.4	6

#	ARTICLE	IF	CITATIONS
235	Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1498-1501.	0.5	6
236	Association Between Minor Salivary Gland Biopsy During Sjögren's Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 686457.	2.2	6
237	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome: Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. <i>Frontiers in Medicine</i> , 2021, 8, 668173.	1.2	6
238	Laboratory Assessment of Patients with Suspected Rheumatic Musculoskeletal Diseases: Challenges and Pitfalls. <i>Current Rheumatology Reviews</i> , 2018, 15, 27-43.	0.4	6
239	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. <i>Clinical Rheumatology</i> , 2022, 41, 641-647.	1.0	6
240	An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 107-114.	0.4	6
241	Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 97-106.	0.4	6
242	Vitamin D increases the production of IL-10 by regulatory T cells in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 76-81.	0.4	6
243	Microchimerism in Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 1039-1040.	0.5	5
244	Low-Dose Aspirin as Primary Prophylaxis for Cardiovascular Events in Rheumatoid Arthritis: An Italian Multicentre Retrospective Study. <i>Cardiology Research and Practice</i> , 2019, 2019, 1-7.	0.5	5
245	Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis. <i>Journal of Dermatological Treatment</i> , 2020, 31, 692-697.	1.1	5
246	Haematopoietic stem cell transplantation in systemic sclerosis: Challenges and perspectives. <i>Autoimmunity Reviews</i> , 2020, 19, 102662.	2.5	5
247	Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 931-942.	1.3	5
248	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab015.	0.3	5
249	Adult-onset Still's disease with elderly onset, results from a multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	5
250	Rheumatoid factor in Sjögren's syndrome: The need to target MALT tissue for preventing lymphoma. <i>Arthritis and Rheumatology</i> , 2016, 68, n/a-n/a.	2.9	4
251	Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study. <i>Clinical and Experimental Medicine</i> , 2020, 20, 31-37.	1.9	4
252	Interplay of anti-SSA/SSB status and hypertension in determining cardiovascular risk in primary Sjögren's syndrome. <i>Journal of Internal Medicine</i> , 2020, 287, 214-215.	2.7	4

#	ARTICLE	IF	CITATIONS
253	Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e103-e103.	0.5	4
254	POS0177â€¦POTENTIAL INVOLVEMENT OF IL-40 AND IL-40-PRODUCING CELLS IN PRIMARY SJOGREN'S SYNDROME (pSS) AND pSS-ASSOCIATED LYMPHOMA. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 301.2-302.	0.5	4
255	Anakinra effectiveness in refractory polyserositis: An Italian multicenter study. <i>Joint Bone Spine</i> , 2022, 89, 105299.	0.8	4
256	Diagnostic and interventional radiology fundamentals of synovial pathology. <i>Acta Biomedica</i> , 2020, 91, 107-115.	0.2	4
257	Gamma/delta T cells in placenta and skin: their different functions may support the paradigm of microchimerism in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2004, 22, S28-30.	0.4	4
258	Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1123-1124.	0.4	4
259	What could we learn from the sub-analysis of a single nation cohort in a worldwide study? Lessons from the results observed in the Italian cohort of the GO-MORE trial. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 623-629.	0.4	4
260	Aerobiological survey in L'Aquila (Italy) throughout 1988 to 1990. <i>Aerobiologia</i> , 1992, 8, 359-363.	0.7	3
261	Use of Rituximab in the Management of Sjögren's Syndrome. <i>Current Treatment Options in Rheumatology</i> , 2015, 1, 277-291.	0.6	3
262	The challenge to interpret conflicting results and the need of a univocal definition for germinal centres in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212108.	0.5	3
263	Adipose stromal vascular fraction and regenerative therapy in SSc: response to the article by Magalon et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e53-e53.	0.5	3
264	Response to: "Correspondence on "Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease" by Muraviov and Muraviova. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e233-e233.	0.5	3
265	Isolated "puffy hands" following COVID-19: clue to a long-term capillary leakage syndrome?. <i>Clinical Rheumatology</i> , 2021, 40, 3863-3864.	1.0	3
266	Infection and Systemic Sclerosis. , 2004, , 613-622.		3
267	The hyper-expression of NLRP4 characterizes the occurrence of macrophage activation syndrome assessing STING pathway in adult-onset Still's disease. <i>Clinical and Experimental Immunology</i> , 2022, 208, 95-102.	1.1	3
268	Correlation between ESSDAI and ClinESSDAI in a real-life cohort of patients with Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 546-547.	0.4	3
269	T helper 1 response is correlated with widespread pain, fatigue, sleeping disorders and the quality of life in patients with fibromyalgia and is modulated by hyperbaric oxygen therapy. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 116, 81-89.	0.4	3
270	Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trial. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 403-406.	0.4	3

#	ARTICLE	IF	CITATIONS
271	Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis. <i>Scientific Reports</i> , 2022, 12, 5125.	1.6	3
272	Inflammation and Dysmetabolism in Systemic Autoimmune Diseases. <i>Journal of Immunology Research</i> , 2019, 2019, 1-2.	0.9	2
273	Advanced diagnostic imaging and intervention in tendon diseases. <i>Acta Biomedica</i> , 2020, 91, 98-106.	0.2	2
274	Prevalence and significance of anti-saccharomyces cerevisiae antibodies in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 73-79.	0.4	2
275	Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 245-256.	0.4	2
276	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 85-94.	0.4	2
277	Novel biomarker for pulmonary vascular disease in systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	2
278	Sociodemographic factors in fibromyalgia: results from the Italian Fibromyalgia Registry. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	2
279	FR10437â€¦Decreased Expression of Angiopoietin 1 on Perivascular Mesenchymal Stem Cells from SSC Patients Induces an Anti Angiogenetic Effect, when Co-Cultured with Endothelial Cells. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 585.2-585.	0.5	1
280	THU0341â€¦Correlation between ESDAI and ClnessDAI in A Real-Life Cohort of Sjögren's Syndrome Patients: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 310.2-310.	0.5	1
281	Mesenchymal Stem Cell Transplantation in Systemic Sclerosis: Comment on the Article by Maria et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 2348-2348.	2.9	1
282	AB1203-HPRâ€¦Comparison of quality of life of patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis with treatment or prescription of biologic drugs: results from the cara study. , 2017, , .		1
283	Tailored approach to rheumatoid arthritis treatment with TNF inhibitors: where do we stand?. <i>Rheumatology</i> , 2018, 57, vii1-vii4.	0.9	1
284	Response to: â€œCorrespondence on â€œLung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligenceâ€œ radiological differencesâ€™ by Ruscitti<i>et al</i>â€™ by Chen<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e221-e221.	0.5	1
285	Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110371.	1.2	1
286	Correspondence on â€œDisease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritisâ€™. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e119-e119.	0.5	1
287	POS0326â€¦ROLE OF THE IL-25 / IL-17RB AXIS IN TH9 POLARIZATION IN PATIENTS WITH PROGRESSIVE SYSTEMIC SCLEROSIS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 390-391.	0.5	1
288	THU0265â€¦THYMIC STROMAL LYMPHOPOIETIN (TSLP) AS A BIOMARKER OF PRIMARY SJÖGRENâ€™S SYNDROME (PSS) AND RELATED LYMPHOMA: VALIDATION IN INDEPENDENT COHORTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 359.1-360.	0.5	1

#	ARTICLE	IF	CITATIONS
289	Long-term safety of rituximab in primary Sjögren's syndrome: the experience of a single centre. <i>Journal of Rheumatology</i> , 2021, , jrheum.210441.	1.0	1
290	Budget Impact Analysis of anakinra in the treatment of patients with Stillé's Disease. <i>Global & Regional Health Technology Assessment</i> , 2020, 7, 72-80.	0.2	1
291	Fibromyalgia severity according to age categories: results of a cross-sectional study from a large national database. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	1
292	Comment on: Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion: reply. <i>Rheumatology</i> , 2008, 47, 1439-1440.	0.9	0
293	Potential of stem cells in the treatment of rheumatic disease. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 183-195.	0.3	0
294	Erratum to "œls minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: A retrospective study" [Semin Arthritis Rheum 44 (2014) 314-324]. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, e23.	1.6	0
295	THU0393...IL-17 Producing Pathogenic T Lymphocytes Co-Express CD20 and are Depleted by Rituximab in Primary sjögren's Syndrome: A Novel Target for an Old Weapon. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 339.1-339.	0.5	0
296	SAT0377...Interferon Gamma-Inducible Protein 16 (IFI16) in Primary Sjögren's Syndrome: A Novel Player in Disease Pathogenesis?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 795.4-796.	0.5	0
297	Novel Therapeutic Strategies in Sjögren's Syndrome. , 2016, , 273-289.		0
298	AB0328...What Could We Learn from The Sub-Analysis of A Single Nation Cohort in A Worldwide Study? Lesson from The Results Observed in The Italian Cohort of The GO-MORE Trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1013.2-1013.	0.5	0
299	Comment on "Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?". <i>Autoimmunity Reviews</i> , 2016, 15, 202.	2.5	0
300	OP0044...Antibodies anti-saccharomyces cerevisiae in primary sjögren's syndrome: prevalence, clinical associations and possible cross-reactivity with disease specific autoantigens. , 2017, , .		0
301	SAT0284...Association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary sjögren's syndrome. , 2017, , .		0
302	THU0164...Subclinical atherosclerosis and cardiovascular events in italian patients with rheumatoid arthritis: results from multicenter girrcs (gruppo italiano di ricerca in reumatologia clinica e) Tj ETQqO O 0 rgBT /Overlock 10 T6 50 217 T		0
303	THU0634...Comparing preferences of patients with rheumatic diseases, of rheumatologists, nurses and pharmacists toward the treatment of rheumatic diseases with biological agents: results from the cara study. , 2017, , .		0
304	SAT0739-HPR...Patients' preferences toward characteristics of treatment with biological agents differ according to experience with their rheumatic disease and treatment received or prescribed: results from the cara study. , 2017, , .		0
305	SAT0313...Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients. , 2017, , .		0
306	Inhibiting inflammatory cytokines in adult onset Stillé's disease. Current trends and new therapeutic perspectives. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 547-554.	0.5	0

#	ARTICLE	IF	CITATIONS
307	POS1349â€¦..THE JOINT INVOLVEMENT IN ADULT ONSET STILLâ€™S DISEASE IS CHARACTERISED BY A PECULIAR MAGNETIC RESONANCE IMAGING AND A SPECIFIC TRANSCRIPTOMIC PROFILE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 957.1-957.	0.5	0
308	Autoimmune screening before adenovirus vector-based DNA vaccine in women may avoid underuse for all the subjects. <i>Neurological Sciences</i> , 2021, 42, 5421-5423.	0.9	0
309	SAT0290â€¦..A Higher Disease Activity in Anti-Ssa/ssb Positive SjÃ¶gren's Syndrome Is Explained by A Higher Clinical and Biological B-Cell Activation: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 773.2-773.	0.5	0
310	FRI0414â€¦..Evaluation of a novel multi-analyte assay for the detection of autoantibodies in the diagnosis of systemic sclerosis. , 2018, , .		0
311	SAT0641â€¦..Performance and agreement of different operators and histological techniques for the assessment of germinal centres in minor salivary glands in primary sjÃ¶grenâ€™s syndrome. , 2018, , .		0
312	Significance of anti-La/SSB antibodies in primary SjÃ¶gren's syndrome patients with combined positivity for anti-Ro/SSA and salivary gland biopsy. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 53-56.	0.4	0
313	Validation of thymic stromal lymphopoietin as a biomarker of primary SjÃ¶gren's syndrome and related lymphoproliferation: results in independent cohorts. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 189-194.	0.4	0
314	Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.4	0
315	Patrick-FABER test in detecting active sacroiliitis in spondyloarthritis patients: a prospective study using magnetic resonance as reference standard. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	0
316	Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	0
317	Title is missing!. , 2020, 15, e0235326.		0
318	Title is missing!. , 2020, 15, e0235326.		0
319	Title is missing!. , 2020, 15, e0235326.		0
320	Title is missing!. , 2020, 15, e0235326.		0
321	Influence of the age at diagnosis in the disease expression of primary SjÃ¶gren syndrome. Analysis of 12,753 patients from the SjÃ¶gren Big Data Consortium.. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 133, 166-174.	0.4	0
322	Patrick-FABER test in detecting active sacroiliitis in spondyloarthritis patients: a prospective study using magnetic resonance as reference standard.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0